

Special Article

Equity in Respiratory Health: Actionable Recommendations for Spain



Carlos Almonacid^{a,*}, Joan B. Soriano^{b,c,d,1}, M. Guadalupe Fontán^e,
Beatriz González López-Valcárcel^f, Carmen Hernández^{g,h}, Rafael Manzanera^{h,i}, Remedios Martel^{a,j},
Mariano Pastor^{k,l}, Virginia Rodríguez^{m,n}, Isabel Urrutia^o, Raquel Varas-Doval^p, Eusebi Chiner^q

^a Servicio de Neumología, Hospital Universitario Puerta de Hierro Majadahonda, Grupo de Trabajo Determinantes Sociales de la Salud Respiratoria de la Sociedad Española de Neumología y Cirugía Torácica, Madrid, Spain

^b Servicio de Neumología, Hospital Universitario La Princesa, Grupo de Trabajo Determinantes Sociales de la Salud Respiratoria de la Sociedad Española de Neumología y Cirugía Torácica, Madrid, Spain

^c Centro de Investigación Biomédica en Red en Enfermedades Respiratorias, Madrid, Spain

^d Comité Nacional Para la Prevención del Tabaquismo, Madrid, Spain

^e Instituto Español de Investigación Enfermera, Consejo General de Enfermería de España, Madrid, Spain

^f Facultad de Economía, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain

^g Centro de Salud La Guareña, Fuentesauco, Spain

^h Grupo de Respiratorio en Atención Primaria, Barcelona, Spain

ⁱ Ingeniería Biomédica, Universitat Pompeu Fabra (UPF), Barcelona, Spain

^j Exdirectora de Salud Pública y Ordenación Farmacéutica de la Junta de Andalucía, Spain

^k Federación Española de Asociaciones de Pacientes Alérgicos y con Enfermedades Respiratorias, Madrid, Spain

^l Foro Español de Pacientes, Madrid, Spain

^m Comisión de Relación con las Asociaciones de Pacientes de la Sociedad Española de Alergología e Inmunología Clínica, Madrid, Spain

ⁿ Servicio de Alergología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

^o Unidad de Asma y Enfermedades Ocupacionales-Medioambientales, Servicio de Neumología, Hospital Universitario Galdakao-Usansolo, Coordinadora del Grupo de Trabajo de Determinantes Sociales de la Salud Respiratoria de la Sociedad Española de Neumología y Cirugía Torácica, Bizkaia, Spain

^p Área de Campañas Sanitarias, Dirección de Servicios Farmacéuticos, Consejo General de Colegios Oficiales de Farmacéuticos, Madrid, Spain

^q Servicio de Neumología, Hospital Universitario San Juan de Alicante, Grupo de Trabajo Determinantes Sociales de la Salud Respiratoria de la Sociedad Española de Neumología y Cirugía Torácica, Alicante, Spain

ARTICLE INFO

Article history:

Received 12 June 2025

Accepted 7 August 2025

Available online 1 September 2025

Keywords:

Chronic respiratory diseases

Equity

Inequalities

Social determinants of health

Healthcare professionals

Social care

ABSTRACT

Chronic respiratory diseases are a major public health burden, affecting over 7 million people in Spain and representing the third leading cause of death. Conditions such as chronic obstructive pulmonary disease, asthma, and lung cancer are heavily influenced by social and environmental determinants, including socioeconomic status, air quality, and smoking. Moreover, the increasingly aging Spanish population and persistent urban pollution levels further expand the burden of these diseases. This article underscores the urgent need to address inequities in respiratory healthcare through comprehensive policy action. To this end, we herein propose measures such as strengthening primary care to ensure early diagnosis, enhancing coordination between community pharmacy, primary and hospital care, incorporating specialised roles such as continuity-of-care nurses, prioritising access to cost-effective innovative treatments, promoting healthy environments, and reinforcing anti-smoking initiatives. We also advocate for inclusion of social determinants of health indicators in electronic health records and for development of patient education programmes. Tackling respiratory health disparities requires targeted strategies that involve all healthcare and social stakeholders to optimise resource use and improve the quality of life of patients with respiratory diseases in Spain.

© 2025 Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: caralmsan@gmail.com (C. Almonacid).

¹ These authors share first authorship.

Equidad en la salud respiratoria: recomendaciones prácticas para España

R E S U M E N

Palabras clave:

Enfermedades respiratorias crónicas
Equidad
Desigualdades
Determinantes sociales de la salud
Profesionales sanitarios
Atención social

Las enfermedades respiratorias crónicas representan una importante carga para la salud pública, afectando a más de siete millones de personas en España, y constituyendo la tercera causa de muerte. Afecciones como la enfermedad pulmonar obstructiva crónica (EPOC), el asma y el cáncer de pulmón están fuertemente condicionadas por determinantes sociales y medioambientales, entre los que se incluyen el nivel socioeconómico, la calidad del aire y el tabaquismo. Además, el progresivo envejecimiento de la población española y los persistentes niveles de contaminación urbana agravan aún más esta carga. El presente artículo subraya la necesidad urgente de abordar las desigualdades en la atención respiratoria mediante una acción política integral. Con este objetivo, se proponen medidas como el refuerzo de la atención primaria para garantizar un diagnóstico precoz, la mejora de la coordinación entre la farmacia comunitaria, la atención primaria y hospitalaria, la incorporación de roles especializados como las enfermeras de continuidad asistencial, la priorización del acceso a tratamientos innovadores coste-efectivos, la promoción de entornos saludables y el refuerzo de las iniciativas antitabaco. Asimismo, se aboga por la inclusión de indicadores de los determinantes sociales de la salud en las historias clínicas electrónicas, y por el desarrollo de programas de educación para pacientes. Abordar las desigualdades en salud respiratoria requiere estrategias específicas que involucren a todos los agentes sanitarios y sociales, con el fin de optimizar el uso de recursos, y mejorar la calidad de vida de los pacientes con enfermedades respiratorias en España.

© 2025 Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

Introduction

Respiratory health is essential for overall health and well-being. Respiratory diseases remain largely underrecognised by many sectors of the population and, therefore, underdiagnosed and undertreated, despite their significant burden.¹ In Europe alone, respiratory conditions are one of the leading causes of morbidity and mortality, generating an annual social cost of €803.5 billion in the European Union as of 2021.² Worldwide, over a billion people – approximately one-eighth of the total population – live with a chronic respiratory disease. Among these, over 200 million have chronic obstructive pulmonary disease (COPD), approximately 300 million people have asthma, and over 50 million people have occupational lung disease.³ Beyond lung cancer and communicable respiratory diseases, other chronic respiratory conditions include obstructive sleep apnoea, interstitial lung disease, pulmonary arterial hypertension, and bronchiectasis.^{4,5}

Chronic respiratory diseases are a major driver of worldwide health loss, together with cancer, diabetes, and cardiovascular disease, some of which may be present in multimorbidity.^{6–11}

With over 14% of the population in Spain affected,¹ chronic respiratory diseases are a major source of physical, emotional, and financial strain for patients, caregivers, the health system, and society at large. Indeed, chronic respiratory diseases were the third leading cause of death in Spain in 2022 (following cardiovascular disease and cancer). Further, it was estimated that combining deaths from lung cancer, tuberculosis, and COVID-19 with those of all chronic respiratory diseases led to a total respiratory mortality in Spain in 2022 that surpassed cancer and came close to cardiovascular disease mortality.¹²

Respiratory diseases accounted for approximately 2 million emergency care visits in 2022 in Spain.¹³ Patients with respiratory diseases visit primary care services 1.4 times more frequently than the general population; this figure rises to 2.5 times for COPD, and 3 times for pneumonia.¹³ Care for patients with respiratory diseases often involves multiple specialists, including pulmonologists, allergists, internists, pharmacists, psychologists, and nurses. The burden of chronic respiratory disease in Spain is expected to rise because of the increasingly aging population, among the oldest within the European Union,¹⁴ plus tobacco smoke exposure, among other factors. In Spain, the gap between life expectancy and

healthy life expectancy is 11.1 years, making it one of the countries with the largest difference (Fig. 1).¹⁵ This gap is 3.4 years greater for women than for men – a gender difference surpassed only in Germany.¹⁵ This demographic shift will likely increase the prevalence of all chronic conditions, including the respiratory ones. This trend is exacerbated by increasing air pollution, persistent smoking, and growing vaping among youth. Further changes in epidemiological determinants of mortality and morbidity will impact the prevalence of chronic diseases.^{16,17}

The 2022 Public Health Strategy developed by the Spanish Ministry of Health emphasised the burden of non-communicable diseases, highlighting that cardiovascular diseases, cancer, Alzheimer's disease, and COPD, together accounted for 55% of all deaths in Spain.¹⁶ These chronic diseases are also major drivers for disability, dependence, poor health, and workforce attrition, with substantial socioeconomic costs. Asthma, despite not being included among the top four in mortality, is also associated with a considerable morbidity burden.

In this context, equity becomes a central pillar of public health in Spain, as chronic respiratory diseases disproportionately affect disadvantaged populations due to unequal exposure to risk factors, limited access to healthcare, and disparities in diagnosis, treatment, and health outcomes.¹⁸ Health equity refers to the fair and just opportunity for everyone to be as healthy as possible, which requires addressing and eliminating obstacles such as poverty, discrimination, and unequal access to quality healthcare, education, or housing.¹⁹

Definitions from experts such as Whitehead and Braveman highlight that, while equality and equity are distinct, measuring equity often relies on identifying and reducing health disparities, especially those that are avoidable, unjust, and systemic.^{20,21} Respiratory diseases exemplify this issue, as they often affect the most vulnerable groups due to disproportionate exposure to risk factors and barriers to care. According to the World Health Organization (WHO), reducing and eliminating health inequities is key to fulfilling the promise to 'leave no one behind' and attaining the health-related Sustainable Development Goals (SDGs) that include SDG 3 – good health and well-being – and SDG 10 – reduced inequalities.²²

The effort to improve the healthcare system was long guided by the Triple Aim framework, seeking to improve the patient experi-




Fig. 1. Healthspan–lifespan gap association with life expectancy and disease burden in 183 countries.¹⁵ (A) Bland–Altman plot of the health-adjusted life expectancy and life expectancy. Solid line represents the mean healthspan–lifespan gap. Dotted lines represent the 95% CI for the healthspan–lifespan gap. (B) The healthspan–lifespan gap as a function of years lived with disability per 100 000 persons contributed by noncommunicable diseases. Solid line represents the line of best fit and the shaded ribbon represents the 95% CI for the regression line.



Fig. 2. Quintuple aim for healthcare improvement.

ence, population health, and healthcare costs.²³ This framework evolved to include two additional aims: supporting healthcare professionals²⁴ and promoting equity (Fig. 2).²⁵ This evolution reflects an increasing recognition that achieving value-based care requires actively addressing health disparities, both across populations and in interpersonal care.²⁶ Ensuring equity demands not just technical skill, but also cultural competence, communication, and a commitment to human rights.²⁷

This article provides multidisciplinary recommendations to help address inequity in respiratory health in Spain, with a focus on chronic respiratory diseases. We examine social determinants of health (SDH) and risk factors, the structure and organisation of healthcare systems in Spain, and current initiatives that exemplify good practices in addressing SDH along the patient journey.

Social determinants of health and risk factors

Social determinants of health

SDH comprise the social, cultural, political, financial, and environmental conditions in which people are born, raised, live, work, and age within a community.²⁸ Their unequal distribution among the population results in health inequities.^{29,30} The Commission on Social Determinants of Health, established by the World Health Organization (WHO), introduced in 2007 a framework classifying SDH mainly as either political and socioeconomic, structural (income, education level, social class, gender, ethnicity), or intermediate (psychosocial factors, behaviours, habits, healthcare-related).¹⁸ The Commission's efforts were instrumental in increasing global awareness on SDH.³¹ Following the WHO Commission's landmark work, the Spanish Commission to Reduce Social Health Inequities identified in 2008 four areas of intervention to tackle health disparities: distribution of power, wealth and resources; living and working conditions throughout the life course; health-promoting environments; and healthcare services.¹⁶

Inequities in health arise from the unequal distribution of resources, wealth, and power.³² SDH encompass income, education level, health education, food security, healthy diet, exercise, work conditions, housing, and the environment (see Table 1).^{33–36} There is mounting evidence on the impact of SDH on disease burden. For example, the environment in which a person is raised affects their life expectancy,³⁷ the social gradient in health and disease is observed across various diseases and causes of death,^{38,39} and loneliness is linked to a decline in health.⁴⁰ Loneliness can make people, particularly the elderly, more vulnerable, which poses a challenge to social and health services.¹⁸ In Spain, over 5 million people lived alone in 2022, and this figure is projected to rise to 6 million over the next 15 years.¹⁸

Table 1
Social determinants of health and potential interventions to reduce inequities in respiratory health.

Category	Determinants	Possible respiratory health inequities	Specific interventions
Biological	Age	Children and elderly	Respiratory health protection in extreme age groups
	Gender	Gender bias and disparities	Improved research and healthcare education
	Marital status	Deterioration based on processes and life stages	Detection and prevention
Lifestyle	Ethnic minorities	Inequities associated with Roma, Latino, and others	
	Smoking	Higher prevalence of respiratory diseases in smokers and passive exposure in populations with less access to smoke-free spaces	Strengthen tobacco control with stricter regulations; accessible smoking cessation programs for all populations
	Other lifestyle habits	Overweight/obesity; exercise/sedentary lifestyle	Emphasis on promoting overall and respiratory health
	Sexual identity	Anxiety/depression/mental health in the LGBTQ+ community	Increased collaboration with civil society
	Socioeconomic level	Higher prevalence of COPD, asthma, and lung cancer in lower-income/education populations with greater exposure to risk factors (e.g. smoking, pollution)	Prevention programs targeting vulnerable populations; equitable access to innovative treatments; specific public health campaigns
	Disease awareness	Low scientific and medical culture in vulnerable populations	Awareness campaigns
	Digital health divide	Inequity in access to telemedicine, affecting aging populations and areas with poor connectivity	Development of digital literacy strategies, ensuring connectivity in rural areas and interoperability of digital health records
	Adherence	Poor adherence in vulnerable populations	Educational campaigns; more support for nursing
Social	Family	Unwanted loneliness	
	Religion		
	Neighbours and community	Integration	Welfare state
	Unemployment	Worse overall health in unemployed individuals	
	Migration	Undocumented migrants have worse health	Specific campaigns
	Prison		
Environmental	Home/dwelling	Worse living conditions in homes of respiratory disease patients	Awareness and education
	Pollution	While ubiquitous, greater impact of air pollution on individuals with chronic diseases	Implement pollution reduction policies; air quality monitoring; traffic restrictions in vulnerable urban areas
	Occupation	Work conditions and exposure	Dialogue with unions and employers
	Education	Low knowledge about respiratory diseases and treatments affects therapeutic adherence and prevention	Educational programs for patients; inclusion of community pharmacists for personalised follow-up
	Culture		
	Nutrition	Poor dietary habits affect respiratory health and development	Nutrition education campaigns
	Primary care	Lack of staff and proper equipment in health centres affects diagnosis and monitoring of chronic respiratory diseases	Increase investment in primary care; incorporate continuity care nurses and other specialised profiles
	Access to healthcare services	Difficulty in accessing early diagnosis and treatment due to inter- and intra-regional differences	Improve healthcare coordination. Private healthcare?
Society	Urban/rural	Distance to healthcare centres	Protect depopulated areas
	Hygiene and health	Decline in both	Investment in health and education
	Crisis	Major determinant	General interventions
	Climate Change	Major determinant	Very general interventions

COPD, chronic obstructive pulmonary disease.

Addressing social inequities, especially in vulnerable populations, is key to improving health, and respiratory health in particular.^{32,41–44} The WHO SDH framework has been adapted to chronic respiratory diseases (Fig. 3), to illustrate how socioeconomic inequality directly impacts respiratory health outcomes, especially in vulnerable populations. Indeed, low socioeconomic status is associated with increased respiratory symptoms and risk of respiratory disease mortality.^{45,46} These effects may be related to poor housing quality, exposure to smoking, and environment/atmospheric pollution, which highlights the bidirectional relationship between poverty and health.³² Moreover, socioeconomic and gender inequities have an impact in child respiratory

health.⁴⁷ Access to and understanding of educational resources are influenced by SDH, including health education, income, employment status, and cultural background.⁴⁸ Health education is closely linked to overall education level, and limited knowledge about a disease and its treatment is a key factor affecting adherence to therapy.^{49,50}

There is a need for studies that evaluate the collective impact of SDH on health outcomes, rather than examining individual factors in isolation; standardised criteria and global methodologies are also needed to holistically assess the impact of SDH. Establishing a unified approach to assess SDH, not only within Spain but also at an international level, would be highly valuable. Additionally,




Fig. 3. Social determinants of respiratory health model. Reproduced with permission from Harper et al.⁴²

further data on the effectiveness of community-based programs – including those led by pharmacies – would provide important insights.^{51–53}

Risk factors

SDH influence both the diseases affecting a population and the risk factors to which individuals are exposed.¹⁸ Smoking is a key risk factor in respiratory health, as it causes and/or exacerbates respiratory and non-respiratory diseases. It is also associated with six of the eight main causes of death worldwide.

In Spain, tobacco control policies introduced in 2006 and 2011 led to a decline in smoking prevalence over the past 15 years,⁵⁴ with 2024 marking the lowest number of smokers in the past 30 years.⁵⁵ Despite this progress, smoking remains the leading risk factor for disability-adjusted life years in Spain.⁵⁶ Smoking is strongly influenced by gender and socioeconomic factors,⁵⁷ and both prevalence and intensity of smoking in Spain increase in groups of lower social class and lower level of education.⁵⁸ Significant decreases of smoking in men were not seen in women, as female smoking prevalence plateaued a decade ago in Spain.⁵⁹ As such, these and other determinants should be considered in policies that address smoking.

Environmental factors have a major impact on health. In fact, four of the top five causes of mortality in Spain are linked to environmental risk factors; for instance, 33.3% of COPD mortality risk was related to environmental factors in Spain 2021.⁶⁰

Exposure to air pollutants contributes to the onset or worsening of chronic respiratory diseases, as pollutants induce oxidative stress and inflammation, particularly in people with pre-existing conditions.⁶¹ Patients with chronic respiratory diseases show increased susceptibility to airborne pollutants due to impaired lung function and immune responses.⁶¹ Notably, nine out of ten people worldwide breathe polluted air, according to the WHO.⁶² Air quality is important outdoors but also inside homes and classrooms,⁶³ which are related to socioeconomic factors. Exposure to green spaces in childhood has been linked to improved lung function, but unequal access, especially limited in low-income neighbourhoods, highlights inequities in health.^{18,64,65} Children are particularly vulnerable to air pollution because of their faster breathing rate and immature respiratory and immune systems, among others.¹⁸ On this note, 26% of mortality in children under five years can be attributed to environmental factors.⁶⁶ Moreover, lower socioeconomic status is a risk factor for hospitalisation of patients with chronic respiratory disease.⁶⁷ Exposure to environmental factors such as mould, tobacco smoke, and coal burning have been linked to a higher prevalence of respiratory symptoms and asthma.⁶⁸ The location where a person lives – both rural vs urban and even postal codes within an urban area – plays a role in health equity.⁶⁹ Another risk factor affecting health is climate change, which should be considered in policies addressing health inequity.³⁷ Overall, socioeconomic and environmental factors lead to health inequities in patients with chronic respiratory diseases, who also are affected by loneliness.

Functioning and organisation of healthcare systems in Spain

The healthcare system is one of the health determinants, and equity in access to healthcare services and coordinated care can pave the way to equity in health.^{31,70} While not the most influential SDH, it can either reduce or worsen health inequities depending on how care is delivered and accessed. The National Healthcare System in Spain follows the Beveridge model (universal and financed by taxes) and was decentralised in 2002. Each autonomous community manages healthcare separately, which may lead to inter- and intra- regional disparities. Addressing these inequities requires strong coordination between healthcare levels across regions.

The role of primary care

Healthcare systems that prioritise primary care as the basic point of entry, as in Spain, are more effective in reducing health inequities.^{37,71,72} This aligns with Starfield's principles: first contact access, continuity, coordination, and comprehensiveness, and derivatives, such as community and family focus, and quality orientation.

Even though adequate primary care is essential, its funding in Spain has not grown in line with its relevance. Instead, investment has continued to focus on hospital care and specialised services.⁷³ Primary care in Spain currently faces serious challenges, including shortages in human resources and infrastructure, professional burnout, organisational problems, and the design of incentives. These issues have contributed to growing difficulties such as limited integration of community pharmacies into the public health system, increased workload, and longer waiting times.⁷⁴

Timely diagnosis of chronic respiratory diseases is highly dependent on primary care, yet access to essential diagnostic tools, such as spirometry, co-oximetry, and thoracic imaging, remains limited.⁷⁵ Management of chronic respiratory diseases requires coordination between primary, hospital, social, and home care. Case manager nurses and liaison nurses play a key role by helping reduce hospital stays; improving communication between healthcare professionals, patients, and caregivers; personalising follow-up care after discharge; and reducing emergency visits.^{76,77} Social workers and pharmacists also contribute considerably to patient follow-up, besides pharmacists supporting correct treatment administration and adherence.^{78,79}

The WHO and Spain's Ministry of Health recommend integrating community pharmacies into the care for patients with chronic diseases and promoting bidirectional communication with primary care.^{72,80}

Technology may help reduce health inequities, for example through telemedicine or telepharmacy, but it also involves certain challenges⁴²; digital literacy gaps, especially among the elderly and rural populations, may drive inequities if not adequately addressed.⁸¹ Interoperability of clinical records across regions is needed, along with standardised data systems. Clinical records should also include indicators related to SDH to allow more efficient follow-up. The development of relevant indicators in different healthcare settings, and the establishment of their thresholds should require additional resources and investment for achieving true implementation research.^{82,83}

'Health area committees' that link primary care with community pharmacy services can help detect local health inequities and find available resources to mitigate them. Prioritising equity in the care of respiratory diseases will ultimately improve outcomes for these and other chronic conditions.

The role of hospital care

Pneumologists, allergologists, and internal medicine specialists play a fundamental role in the diagnosis and management of patients with chronic respiratory diseases, particularly the most severe ones.⁸⁴ Together with nursing, these specialists conduct follow-up of high-risk patients, prescribe treatment, coordinate with other healthcare levels, and contribute to research, education, and prevention of chronic respiratory diseases, which ultimately leads to better outcomes and improving the quality of life of patients.⁸⁴ A multidisciplinary approach is needed to address SDH, involving ongoing education for healthcare professionals to help prevent or mitigate the impact of respiratory diseases. This not only benefits patients but also promotes health equity.

The importance of optimising coordination of care

Primary care serves as the gateway to the healthcare system and plays a key role in coordinating community elements, such as community pharmacy, sport facilities, schools, and nursing homes. Promoting bidirectional communication among these sectors is essential to expedite care for patients with chronic respiratory diseases. This coordination must always be adapted to the geographical characteristics and the healthcare structure of a given area.

To address SDH, a comprehensive care approach needs to consider improved interpersonal communication, coordinated care, and community involvement.⁸⁵ Integrating SDH in respiratory care can improve patients' quality of life and contribute to reducing health inequities. This requires coordination between primary and hospital care, pharmacy, community services, and various health professionals to promote policies that improve social and environmental factors to reduce the incidence of respiratory diseases.

Good practices and initiatives of interest

Several initiatives have been adequately implemented across Spain to address social, environmental, and behavioural determinants that contribute to inequities in respiratory health. These programmes, developed by professional societies, local governments, and community organisations, aim to improve awareness, education, access to care, and social support for vulnerable populations. Below are some examples that illustrate ongoing efforts to reduce disparities and promote more equitable respiratory healthcare; these best practices may be expanded or adapted elsewhere.

Working group on social determinants of health

The Spanish Society of Pneumology and Thoracic Surgery (SEPAR) developed a working group focused on social determinants of respiratory health.³² The working group aims to provide evidence-based information on these determinants, promote training on this topic, strengthen ties with healthcare professionals, and advise the board of directors of SEPAR on improving communication with health authorities.

SEPAR patients

Patients with respiratory diseases face unexpected situations on a daily basis. The working group SEPARpatients was developed by SEPAR to educate patients, relatives, and caregivers on managing respiratory diseases and making informed decisions.⁸⁶ This initiative also promotes social awareness of respiratory diseases.

Asthma Right Care

The Respiratory Group in Primary Care (GRAP) developed the Asthma Right Care initiative in Spain, targeting primary care physicians and community pharmacists, through the General Pharmaceutical Council of Spain. The goal of the initiative is to raise awareness on the negative impact of overusing short-acting beta-agonists in patients with asthma (increased exacerbations and mortality⁸⁷), especially in patients who primarily use this rescue therapy as the main treatment approach without adequate maintenance treatment according to guidelines.⁸⁸

'I am an allergy expert'

The project 'I am an allergy expert' was developed in 2018 by the Spanish Society of Allergology and Clinical Immunology (SEAC) to educate patients, relatives, and caregivers on the most prevalent allergic diseases.⁸⁹ A website was developed with information for teenagers and adults. The initiative also aims to establish a support network and bring patient associations to light.

Radars

The Radars project was initiated by the social services of Barcelona city council to make neighbourhoods more humane, safe, participatory, and supportive.⁹⁰ The goal is to mitigate loneliness in the elderly and have a network of participants (neighbours, businesses, pharmacies) that can notify social services about elderly people who might need help.

'Madrid is with you'

Madrid city council developed the 'Madrid is with you' initiative to build connections between volunteers and Madrid city residents aged 65 and above.⁹¹ The goal is to mitigate loneliness in elderly residents, who can request a volunteer for assistance with everyday tasks, leisure activities, and medical appointments.

'Rural health schools'

The 'Rural health schools' Project was launched in 2023 by the General Pharmaceutical Council of Spain and the Castilla y León Pharmaceutical Council to provide healthcare education and promote health in rural areas in Castilla y León.⁹² Through training sessions for different population groups, the programme aimed to strengthen economic, social, and territorial cohesion in vulnerable rural areas, improve residents' health and quality of life, and reinforce the role of pharmacists in guiding and supporting patients.

'Accessible medication plus' app

A free mobile application, 'Accessible medication plus' was developed by the General Pharmaceutical Council of Spain, ONCE Foundation, and Fundación Vodafone España to enable access to updated medication information by anyone who uses the app.⁹³ A user can create a profile with key information, such as allergies or pregnancy status, allowing the app to alert them about any potential incompatibility with medications they search for. The app was developed to be accessible to people with visual and/or hearing impairment, and the elderly.

Recommendations

As a result of this review, we have identified a need for a pragmatic country-wide strategy that promotes coordinated management of respiratory diseases, considers equity, and evaluates the

impact of SDH. Ultimately, this approach would optimise the respiratory diseases patient journey and enable respiratory diseases to be considered specifically in healthcare policy. This strategy should be developed by the public administration (healthcare and social services), all healthcare levels (primary, hospital, and community care) involved directly or indirectly in care for respiratory diseases, and scientific societies, general councils, and patient associations. This approach could be enhanced by reinforcing existing regulations and implementing public policies to create and protect healthy environments (particularly focused on reducing smoking and improving air quality). Our role as an independent party is limited to raise the flag and identify the unmet needs related with chronic respiratory diseases. Future engagement of the relevant autonomic and national authorities should address on the who/what/how/when additional financial and human resources necessary to tackle them in full.

To ensure equity, the consensus group proposes the following recommendations:

- R1. Ensure a holistic and comprehensive approach to manage patients with chronic respiratory diseases by coordinating different healthcare levels (primary, hospital, and community care) and public administration departments (health and social services). This requires:
 - a. Developing comprehensive care plans for respiratory diseases.
 - b. Establishing reference centres or specialised units for respiratory conditions of varying complexity.
 - c. Promoting accreditation programs for nurses with advanced competencies in respiratory care and strengthening case manager and liaison nurse roles in all health centres.
 - d. Enhancing the role of nurses specialised in family and community care to promote health and prevent disease, especially in vulnerable areas.
 - e. Including some key SDH data in a unified clinical record.
 - f. Strengthening health councils as tools to identify the SDH affecting each health area.
 - g. Expanding the role of pharmacies (primary, hospital, and community care) in treatment support, health literacy, and patient counselling.
- R2. Facilitate early diagnosis of respiratory diseases by strengthening the role of primary care and its coordination with specialised care by training and providing quick access to diagnostic tests and tools (e.g. spirometry, chest imaging) when there is clinical suspicion.
- R3. Consider available resources and prioritisation strategies, promote equitable access to treatment and inclusion of cost-effective therapeutic innovations focusing on equity across regions, individuals, and healthcare services.
- R4. Implement therapeutic education programs and healthy lifestyle recommendations to empower patients and caregivers in managing the disease and improving treatment adherence during follow-up and treatment.
- R5. Launch awareness campaigns across all regions to strengthen prevention efforts and promote respiratory health.
- R6. Establish quality indicators that allow regions to measure and evaluate the efficiency of chronic respiratory disease management using the same agreed-upon criteria.
- R7. Assign the following responsibilities to the future State Agency for Public Health, which has been proposed in a draft bill approved by the Council of Ministers of Spain:
 - a. Develop a unified methodology to continuously analyse and monitor the impact of SDH on respiratory diseases from a multidisciplinary and interregional perspective.

- b. Identify key SDH data that should be integrated as indicators in the unified clinical record.

Other potential obstacles to overcome include resistance to change, data privacy issues, or lack of interdepartmental coordination with and beyond primary care. Again, in due course any corrective strategies should require a dialogue with all relevant authorities.

Beyond authorities at the autonomic and national levels, any particular project/program targeting vulnerable populations should require the active engagement of representatives from the respective communities – such as migrants (civil society, Red Cross, ...), ethnic minorities (Roma, Latino, and other representatives), LGTBIQ+ representatives, rural communities (city halls, politicians, ...), prisoners (inmate representatives and their families, Department of Interior, ...), or children (paediatric societies, parents' associations, Education departments, ...).

Recently, the WHO framed social inequalities as a global strategy to fulfil the health-related SDGs.^{94,95} The work we present here is a further step to implement the WHO's "no one left behind" campaign for people who suffer chronic respiratory disease, and their carers.

Conclusions

Chronic respiratory diseases represent an important and probably underestimated public health issue, characterised by high prevalence and mortality, and associated with a substantial socio-economic burden. These challenges are exacerbated by significant inequities linked to social, environmental, and behavioural determinants such as poverty, pollution, and smoking, among others. Although Spain has a universal healthcare system, inequities persist due to underfunding, regional fragmentation, and technological barriers. To address this, it is essential to implement equity-focused health policies, strengthen coordination between primary, community, and hospital care, promote interventions targeting modifiable determinants, and integrate accessible digital tools. Community-based initiatives and targeted educational programmes have shown preliminary effectiveness and should be expanded to further reduce respiratory health disparities.

Declaration of generative AI and AI-assisted technologies in the writing process

No artificial intelligence tools were used in the conception, writing, or editing of this manuscript.

Funding

This manuscript was sponsored and funded by Chiesi España S.A., providing the necessary financial support for its development.

Authors' contributions

All authors contributed to the development of the manuscript. CA and JBS led the conceptualization, drafting and coordination of the document along with EC. GF, BGLV, CH, RM, MP, VR and IU participated in the meetings held, literature and evidence review, and critical discussion of the document. All authors were involved in iterative rounds of review and approved the final version of the manuscript.

Conflicts of interest

CA has received grants or contracts from EIT Health – ROUTE2SPAIN; consulting fees from GSK, AstraZeneca, Chiesi,

Gebro, and Sanofi; honoraria for lectures, presentations, speaker bureau participation, manuscript writing, or educational events from GSK, AstraZeneca, Chiesi, Gebro, Menarini, Faes, and Sanofi; and support for attending meetings and/or travel from GSK, AstraZeneca, Chiesi, Gebro, Menarini, and Faes.

JBS has received pharmaceutical company grants from 2021 to 2025 from Chiesi, GSK, Linde and Novartis via Hospital Universitario de La Princesa. Participated in speaking activities, advisory committees, and consultancies from 2021 to 2025 sponsored by Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, CNPT, ERS, FTH, Gebro, Grifols, GSK, IHME, Laminar Pharma, Linde, Lipopharma, Menarini, Mundipharma, Novartis, OMS/WHO, Pfizer, ResApp, RiRL, ROVI, SEPAR, SAPIO, Seqirus, WHO EUR, Takeda and Zambon. Finally, he declares never received, directly or indirectly, any funding from tobacco manufacturers or their affiliates.

BGLV has received grants or contracts from Ayuntamiento Las Palmas Gran Canaria and Servicio Canario de la Salud; consulting fees from Centro de Políticas Públicas y de Gobierno, Amgen and Cariotipo MH5 S.L.; honoraria for lectures, presentations, speaker bureau participation, manuscript writing, or educational events from Sociedad Catalana de Gestión Sanitaria, Fundacion Gaspar Casal, Funcas, Barcelona School of Management UPF, Consejo Economico y Social de España, Jakiunde. San Sebastian, CRES (Universidad Pompeu Fabra) and support for attending meetings and/or travel from WHO Europe.

CH has received grants or contracts from Chiesi; honoraria for lectures, presentations, speaker bureau participation, manuscript writing or educational events from Chiesi, GSK, AstraZeneca, Lundbeck, Boehringer Ingelheim, and Mylan; and support for attending meetings and/or travel from Chiesi and GSK.

VR has received support for attending meetings and/or travel from Chiesi.

IU has received grants or contracts from AstraZeneca, Sanofi, Chiesi and GSK; honoraria for lectures, presentations, speaker bureau participation, manuscript writing, or educational events from AstraZeneca, Sanofi and GSK; and support for attending meetings and/or travel from Menarini, GSK, and AstraZeneca.

EC has received grants or contracts from AstraZeneca, Sanofi and GSK; honoraria for lectures, presentations, speaker bureau participation, manuscript writing, or educational events from AstraZeneca, Sanofi and GSK; and support for attending meetings and/or travel from Menarini, GSK, and AstraZeneca.

All other authors declare no conflicts of interest.

Acknowledgements

The authors acknowledge Sara García and Gloria González from Adelphi Targis S.L. for providing editorial and medical writing assistance in preparing this manuscript. Medical writing support was provided by Angela Rynne Vidal, PhD.

References

1. Federación Española de Asociaciones de Pacientes Alérgicos, con Enfermedades Respiratorias. *Propuestas de los pacientes respiratorios a los partidos políticos que concurren a las elecciones generales*; 2023.
2. Internal Respiratory Coalition. Internal respiratory coalition. "Europe." Available from: <https://international-respiratory-coalition.org/countries/europe/>.
3. Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med*. 2020;8:585–96. [http://dx.doi.org/10.1016/S2213-2600\(20\)30105-3](http://dx.doi.org/10.1016/S2213-2600(20)30105-3).
4. Gould GS, Hurst JR, Trofor A, et al. Recognising the importance of chronic lung disease: a consensus statement from the Global Alliance for Chronic Diseases (Lung Diseases group). *Respir Res*. 2023;24. <http://dx.doi.org/10.1186/s12931-022-02297-y>.
5. Shukla SD, Vanka KS, Chavelier A, et al. Chronic respiratory diseases: an introduction and need for novel drug delivery approaches. *Targeting chronic*

- inflammatory lung diseases using advanced drug delivery systems; 2020. p. 1–31, <http://dx.doi.org/10.1016/B978-0-12-820658-4.00001-7>.
6. Sin DD, Doiron D, Agusti A, et al. Air pollution and COPD: GOLD 2023 committee report. *Eur Respir J*. 2023;61, <http://dx.doi.org/10.1183/13993003.02469-2022>.
 7. Xiang Y, Luo X. Extrapulmonary comorbidities associated with chronic obstructive pulmonary disease: a review. *Int J COPD*. 2024;19:567–78, <http://dx.doi.org/10.2147/COPD.S447739>.
 8. Murray CJL. Findings from the Global Burden of Disease Study 2021. *Lancet*. 2024;403:2259–62, [http://dx.doi.org/10.1016/S0140-6736\(24\)00769-4](http://dx.doi.org/10.1016/S0140-6736(24)00769-4).
 9. Ledford DK, Kim TB, Ortega VE, Cardet JC. Asthma and respiratory comorbidities. *J Allergy Clin Immunol*. 2024, <http://dx.doi.org/10.1016/j.jaci.2024.11.006>.
 10. Chang AB, Kovesi T, Redding GJ, et al. Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally. *Lancet Respir Med*. 2024;12:556–74, [http://dx.doi.org/10.1016/S2213-2660\(24\)00008-0](http://dx.doi.org/10.1016/S2213-2660(24)00008-0).
 11. Bhattacharya S, Heidler P, Varshney S. Incorporating neglected non-communicable diseases into the national health program – a review. *Front Public Health*. 2023;10, <http://dx.doi.org/10.3389/fpubh.2022.1093170>.
 12. Peláez A, Soriano JB, Rodrigo-García M, et al. Trends in mortality in Spain, with a special focus on respiratory-related conditions in the midst of the COVID-19 pandemic. *Med Clin (Barc)*. 2024;164:1–9, <http://dx.doi.org/10.1016/j.medcli.2024.08.004>.
 13. Ministerio de Sanidad. Informe Anual Del Sistema Nacional de Salud 2023; 2024. Available from: https://www.sanidad.gob.es/estadEstudios/estadisticas/sisInfSanSNS/tablasEstadisticas/InfAnualSNS2023/INFORME_ANUAL_2023.pdf
 14. Instituto Nacional de Estadística. Tablas de mortalidad. Últimos datos. Available from: <https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica.C&cid=1254736177004&menu=ultiDatos&idp=1254735573002>.
 15. Garmany A, Terzic A. Global healthspan–lifespan gaps among 183 World Health Organization member states. *JAMA Netw Open*. 2024;7, <http://dx.doi.org/10.1001/jamanetworkopen.2024.50241>, e2450241.
 16. Ministerio de Sanidad. Estrategia de Salud Pública 2022 (ESP 2022); 2022. Available from: <https://www.sanidad.gob.es/organizacion/planesEstrategias/saludPublica/docs/Estrategia.de.Salud.Publica.2022.pdf>
 17. Plataforma Cronicidad: Horizonte 2025. La Cronicidad En Las Políticas Públicas Sanitarias. Recomendaciones Para Definir Un Marco Común de Abordaje al Paciente Crónico Complejo; 2024. Available from: <https://www.cronicidadhorizonte2025.com/arxius/imatgesbutlleti/Informe-CH2025-La-cronicidad-en-las-politicas-publicas-sanitarias.pdf>
 18. Consejo General de Colegios Oficiales de Farmacéuticos. Determinantes Sociales de La Salud. Abordaje Desde La Visión de La Sociedad Civil; 2024. Available from: <https://www.farmaceticos.com/wp-content/uploads/2024/02/2024-Informe-Determinantes-Sociales-Salud-Espana-Final.pdf>
 19. Braveman P, Arkin E, Orleans T, et al. What is health equity? *Behav Sci Policy*. 2018;4:1–14, <http://dx.doi.org/10.1177/237946151800400102>.
 20. Whitehead M. The concepts and principles of equity and health. *Int J Health Serv*. 1992;22:429–45, <http://dx.doi.org/10.2190/986L-LHQ6-2VTE-YRRN>.
 21. Braveman P, Gruskin S. Defining equity in health. *J Epidemiol Community Health* (1978). 2003;57:254–8, <http://dx.doi.org/10.1136/jech.57.4.254>.
 22. World Health Organization. World Health Statistics 2022. Monitoring Health for the SDGs; 2022. Available from: <https://iris.who.int/bitstream/handle/10665/356584/9789240051140-eng.pdf>
 23. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. *Health Aff*. 2008;27:759–69, <http://dx.doi.org/10.1377/hlthaff.27.3.759>.
 24. Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. *Ann Fam Med*. 2014;12:573–6, <http://dx.doi.org/10.1370/afm.1713>.
 25. Nundy S, Cooper LA, Mate KS. The quintuple aim for health care improvement: a new imperative to advance health equity. *JAMA*. 2022;327:521–2, <http://dx.doi.org/10.1001/jama.2021.25181>.
 26. García P, Breijo CM. Valoración de la calidad de la atención del Departamento de Ecografía. *Revista Cubana de Tecnología de la Salud*. 2015;6. Available from: <https://revtecnologia.sld.cu/index.php/tec/rt/printerFriendly/420/595>
 27. Instituto Nacional de Salud Pública. Equidad En El Acceso a Los Servicios de Salud; 2021. Available from: <https://insp.mx/assets/documents/webinars/2021/CISS.Equidad.acceso.pdf>
 28. Ministerio de Sanidad. Glosario de Promoción de la Salud. Available from: <https://www.sanidad.gob.es/areas/promocionPrevencion/promoSaludEquidad/equidadYDesigualdad/glosario/home.htm>.
 29. Starfield B. Is primary care essential? *Lancet*. 1994;344:1129–33, [http://dx.doi.org/10.1016/S0140-6736\(94\)90634-3](http://dx.doi.org/10.1016/S0140-6736(94)90634-3).
 30. Marmot M, Friel S, Bell R, et al. Closing the gap in a generation: health equity through action on the social determinants of health. *Lancet*. 2008;372:1661–9, [http://dx.doi.org/10.1016/S0140-6736\(08\)61690-6](http://dx.doi.org/10.1016/S0140-6736(08)61690-6).
 31. Hernández-Aguado I, Santaolaya Cesteros M, Campos Esteban P. Las desigualdades sociales en salud y la atención primaria Informe SESPAS 2012. *Gac Sanit*. 2012;26:6–13, <http://dx.doi.org/10.1016/j.gaceta.2011.09.036>.
 32. Perpiñá-Tordera M, Almonacid C, Vives EC, et al. Social determinants of respiratory health: opening the door. *Arch Bronconeumol*. 2024, <http://dx.doi.org/10.1016/j.arbres.2024.07.022>.
 33. Redmond C, Akinoso-Imran AQ, Heaney LG, et al. Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2022;149:1617–27, <http://dx.doi.org/10.1016/j.jaci.2021.10.007>.
 34. Murphy J, McSharry J, Hynes L, et al. Prevalence and predictors of adherence to inhaled corticosteroids in young adults (15–30 years) with asthma: a systematic review and meta-analysis. *J Asthma*. 2021;58:683–705, <http://dx.doi.org/10.1080/02770903.2020.1711916>.
 35. Rönmark E, Andersson C, Nyström L, et al. Obesity increases the risk of incident asthma among adults. *Eur Respir J*. 2005;25:282–8, <http://dx.doi.org/10.1183/09031936.05.00054304>.
 36. Black MH, Zhou H, Takayanagi M, et al. Increased asthma risk and asthma-related health care complications associated with childhood obesity. *Am J Epidemiol*. 2013;178:1120–8, <http://dx.doi.org/10.1093/aje/kwt093>.
 37. Comisión Sobre Determinantes Sociales de la Salud de la Organización Mundial de la Salud. Subsanar Las Desigualdades de Una Generación. Alcanzar La Equidad Sanitaria Actuando Sobre Los Determinantes Sociales de La Salud; 2008. Available from: <https://iris.who.int/bitstream/handle/10665/69830/WHO-IER-CSDH.08.1-spa.pdf?sequence=1>
 38. Borrell C, Malmusi D, Artazcoz L, et al. Propuesta de políticas e intervenciones para reducir las desigualdades sociales en salud en España. *Gac Sanit*. 2012;26:182–9, <http://dx.doi.org/10.1016/j.gaceta.2011.07.024>.
 39. Whitehead M, Dahlgren G. Concepts and principles for tackling social inequities in health: levelling up. Part 1. World Health Organization; 2006. Available from: https://www.enothe.eu/cop/docs/concepts_and_principles.pdf
 40. Gasull Molinera V. La Soledad. Un Problema de Salud Pública. Available from: <https://semergen.es/files/docs/grupos/salud mental/soledadSaludPublica.pdf>.
 41. Ruiz Álvarez M, Aginagalde Llorente AH, Del Llano Señarís JE. Los determinantes sociales de la salud en España (2010–2021): una revisión exploratoria de la literatura. *Rev Esp Salud Publica*. 2022;96:e1–58. Available from: https://www.sanidad.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdom/VOL96/REVISIONES/RS96C.202205041.pdf
 42. Harper LJ, Kidambi P, Kirincich JM, et al. Health disparities: interventions for pulmonary disease – a narrative review. *Chest*. 2023;164:179–89, <http://dx.doi.org/10.1016/j.chest.2023.02.033>.
 43. Llano JC. Pobreza e Inequidad En Salud: Propuestas de Mejora de Las Políticas de Salud Para La Lucha Contra La Pobreza y La Exclusión Social; 2020. Available from: <https://www.eapn.es/ARCHIVO/documentos/documentos/16092509.74.pobreza-e-inequidad-salud.eapn-web.pdf>
 44. Chiner E, Hernández C, Martínez-García MÁ. The cost of electrical energy. The end point in the precariousness of the chronic respiratory patient. *Arch Bronconeumol*. 2022;58:211–2, <http://dx.doi.org/10.1016/j.arbres.2021.08.009>.
 45. Du M, Zhu L, Liu M, Liu J. Mutual associations of healthy behaviours and socioeconomic status with respiratory diseases mortality: a large prospective cohort study. *Nutrients*. 2023;15, <http://dx.doi.org/10.3390/nu15081872>.
 46. Andersén H, Bhatta L, Bashir M, et al. Is there still a social gradient in respiratory symptoms? A population-based Nordic Espir Lung-study. *Respir Med*. 2024;223, <http://dx.doi.org/10.1016/j.rmed.2024.107561>.
 47. Carriero N, Dalmau-Bueno A, García-Altés A. Socioeconomic inequalities in 29 childhood diseases: evidence from a 1,500,000 children population retrospective study. *BMC Public Health*. 2021;21, <http://dx.doi.org/10.1186/s12889-021-11230-9>.
 48. Urbina M, González MA. La Importancia de Los Determinantes Sociales de La Salud En Las Políticas Públicas; 2012. Available from: <https://www.insp.mx/images/stories/Produccion/pdf/131209.determinantesSociales.pdf>
 49. Farmaindustria. Plan de Adherencia al Tratamiento: Uso responsable del medicamento; 2017. Available from: <https://www.farmaindustria.es/adherencia/>
 50. Consejo General de Colegios Oficiales de Farmacéuticos. Diseño, evaluación del impacto e implantación de un servicio profesional de adherencia terapéutica desde el ámbito de la farmacia comunitaria; 2019. Available from: <https://www.farmaceticos.com/wp-content/uploads/2020/02/2019-informe-resultados-adherenciamed.pdf>
 51. Consejo General de Colegios Oficiales de Farmacéuticos. Medida del impacto clínico, económico y humanístico del servicio de seguimiento farmacoterapéutico en mayores polimedicados, en la farmacia comunitaria española: Informe 2011–2014; 2014. Available from: <https://www.farmaceticos.com/wp-content/uploads/2020/02/Resultados-Definitivos-Programa-Consigue-Impacto-2011-2014.pdf>
 52. Consejo General de Colegios Oficiales de Farmacéuticos. Servicio de conciliación de la medicación al alta hospitalaria coordinada por farmacéuticos de distintos niveles asistenciales: Informe Global Octubre; 2021. Available from: https://www.farmaceticos.com/wp-content/uploads/2019/05/Informe-Concilia-Medicamentos_v09_def-1.pdf
 53. Suárez Álvarez Ó, Fernández-Feito A, Vallina Crespo H, et al. Tools to assess the impact on health of public health programmes and community interventions from an equity perspective. *Gac Sanit*. 2018;32:579–81, <http://dx.doi.org/10.1016/j.gaceta.2018.01.008>.
 54. Piñeiro B, Trias-Llimós S, Spijker JJA, et al. Estimation of smoking-related mortality and its contribution to educational inequalities in life expectancy in Spain: an observational study, 2016–2019. *BMJ Open*. 2022;12, <http://dx.doi.org/10.1136/bmjopen-2021-059370>.
 55. La Moncloa. España registra mínimo histórico en consumo de tabaco en 30 años; 2024. Available from: <https://www.lamoncloa.gob.es/serviciodeprensa/notasprensa/sanidad/14/paginas/2024/031224-minimo-consumo-tabaco.aspx>

56. Soriano JB, Rojas-Rueda D, Alonso J, et al. The burden of disease in Spain: results from the Global Burden of Disease 2016. *Med Clin (Barc)*. 2018;151:171–90, <http://dx.doi.org/10.1016/j.medcli.2018.05.011>.
57. Garrett BE, Martell BN, Caraballo RS, King BA. Socioeconomic differences in cigarette smoking among sociodemographic groups. *Prev Chronic Dis*. 2019;16, <http://dx.doi.org/10.5888/pcd16.180553>.
58. Martín Álvarez JM, Barrientos Marín J, Millán JM. La relación entre el gradiente socioeconómico y el consumo de cigarrillos en España. *Adicciones*. 2022;34:94–109, <http://dx.doi.org/10.20882/adicciones.1403>.
59. Villalbí J, Fernández E. Once upon a time... smoking began its decline among women in Spain. *Tob Prev Cessat*. 2016;2:96–101, <http://dx.doi.org/10.18332/tpc/62020>.
60. Institute for Health Metrics and Evaluation. GBD Compare. Available from: <https://vizhub.healthdata.org/gbd-compare/>.
61. Sierra-Vargas MP, Montero-Vargas JM, Debray-García Y, et al. Oxidative stress and air pollution: its impact on chronic respiratory diseases. *Int J Mol Sci*. 2023;24, <http://dx.doi.org/10.3390/ijms24010853>.
62. Breathelife. Who it Affects. Available from: <https://breathelife2030.org/the-issue/who-it-affects/>.
63. World Health Organization. Air quality, energy and health. Available from: <https://www.who.int/teams/environment-climate-change-and-health/air-quality-energy-and-health/sectoral-interventions/household-air-pollution>.
64. Health and Environment Alliance. Aire Sano. Infancia Más Sana; 2019. Available from: <https://www.env-health.org/wp-content/uploads/2019/07/Madrid-city-report-Healthy-air-healthier-children-spanish.pdf>.
65. Fernandes A, Avraam D, Cadman T, et al. Green spaces and respiratory, cardiometabolic, and neurodevelopmental outcomes: an individual-participant data meta-analysis of >35,000 European children. *Environ Int*. 2024;190, <http://dx.doi.org/10.1016/j.envint.2024.108853>.
66. World Health Organization. Preventing disease through healthy environments. A global assessment of the burden of disease from environmental risks; 2016. Available from: <https://iris.who.int/bitstream/handle/10665/204585/9789241565196-eng.pdf>.
67. Wallar LE, De Prophetis E, Rosella LC. Socioeconomic inequalities in hospitalizations for chronic ambulatory care sensitive conditions: a systematic review of peer-reviewed literature, 1990–2018. *Int J Equity Health*. 2020;19, <http://dx.doi.org/10.1186/s12939-020-01160-0>.
68. Wypych-Slusarska A, Krupa-Kotara K, Niewiadomska E. Social inequalities: do they matter in asthma bronchitis, and respiratory symptoms in children? *Int J Environ Res Public Health*. 2022;19, <http://dx.doi.org/10.3390/ijerph192215366>.
69. Graham GN. Why your ZIP code matters more than your genetic code: promoting healthy outcomes from mother to child. *Breastfeeding Med*. 2016;11:396–7, <http://dx.doi.org/10.1089/bfm.2016.0113>.
70. Solar O, Irwin A. A conceptual framework for action on the social determinants of health; 2010. p. 79. Available from: <http://www.who.int/sdhconference/resources/ConceptualframeworkforactiononSDH-eng.pdf>.
71. Starfield B. The hidden inequity in health care. *Int J Equity Health*. 2011;10, <http://dx.doi.org/10.1186/1475-9276-10-15>.
72. World Health Organization. Primary health care transformation in Spain: current challenges and opportunities: primary health care policy paper series; 2023. Available from: <https://www.who.int/europe/publications/i/item/WHO-EURO-2023-8071-47839-70649>.
73. Ministerio de Sanidad. Estadística de Gasto Sanitario Público 2022; 2024. Available from: <https://www.sanidad.gob.es/estadEstudios/estadisticas/docs/EGSP2008/egspPrincipalesResultados.pdf>.
74. Cordero Vicente L, Sunyer C. El deterioro de la atención primaria: factores que explican la presión asistencial y propuestas para reducirla. *EsadeEcPol Policy Brief*. 2023;39, <http://dx.doi.org/10.56269/20230523/lcb>.
75. Labaki WW, Han MLK. Chronic respiratory diseases: a global view. *Lancet Respir Med*. 2020;8:531–3, [http://dx.doi.org/10.1016/S2213-2600\(20\)30157-0](http://dx.doi.org/10.1016/S2213-2600(20)30157-0).
76. Consejo General de Enfermería. Marco de competencias de las/os enfermeras/os gestoras/es de casos en la atención al paciente con problemas de salud crónicos con complejidad; 2021. Available from: <https://www.consejogeneralenfermeria.org/profesion/guias-clinicas/send/70-competencias-enfermeras/1522-competencias-enfermeras-gestoras-paciente-complejidad-14-07-2021>.
77. Consejo General de Enfermería. Marco de competencias de las/os enfermeras/os en el ámbito de la continuidad asistencial o enlace en la atención al paciente con problemas de salud crónicos; 2021. Available from: <https://www.consejogeneralenfermeria.org/profesion/guias-clinicas/send/70-competencias-enfermeras/1523-competencias-ambito-de-continuidad-asistencial-o-enlace-en-la-atencion-al-paciente-cronico-15-07-2021>.
78. Mahmoud A, Abuhelwa AY, Owen T, et al. Role of pharmacists in the care of adult asthma patients: a scoping review. *Res Soc Adm Pharm*. 2024;20:860–9, <http://dx.doi.org/10.1016/j.sapharm.2024.06.005>.
79. Gentene AJ, Guido MR, Woolf B, et al. Multidisciplinary team utilizing pharmacists in multimodal bundled care reduce chronic obstructive pulmonary disease hospital readmission rates. *J Pharm Pract*. 2021;34:110–6, <http://dx.doi.org/10.1177/0897190019889440>.
80. Ministerio de Sanidad SS e I. Estrategia Para El Abordaje de La Cronicidad En El Sistema Nacional de Salud; 2012. Available from: <https://www.sanidad.gob.es/areas/calidadAsistencial/estrategias/abordajeCronicidad/docs/ESTRATEGIA-ABORDAJE-CRONICIDAD.pdf>.
81. IQVIA. Cronicidad y Estrategias de E-Salud: La Importancia Del Perfil Digital; 2024. Available from: https://plataformadepacientes.org/wp-content/uploads/2024/03/cronicidad_estrategias_e-salud.pdf.
82. Lewis CC, Stanick CF, Martinez RG, et al. The society for implementation research collaboration instrument review project: a methodology to promote rigorous evaluation. *Implement Sci*. 2015;10, <http://dx.doi.org/10.1186/s13012-014-0193-x>.
83. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health*. 2011;38:65–76, <http://dx.doi.org/10.1007/s10488-010-0319-7>.
84. Mangione CM, Barry MJ, Nicholson WK, et al. Screening for chronic obstructive pulmonary disease: US preventive services task force reaffirmation recommendation statement. *JAMA*. 2022;327:1806–11, <http://dx.doi.org/10.1001/jama.2022.5692>.
85. Daniel H, Bornstein SS, Kane GC. Addressing social determinants to improve patient care and promote health equity: an American college of physicians position paper. *Ann Intern Med*. 2018;168:577–8, <http://dx.doi.org/10.7326/M17-2441>.
86. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). SEPARpacientes. Available from: <https://www.separ.es/pacientes>.
87. Molina J, Plaza V, Nuevo J, et al. Clinical consequences of the overuse of short-acting β_2 -adrenergic agonists (SABA) in the treatment of asthma in Spain: the SABINA study. *Open Respir Arch*. 2023;5, <http://dx.doi.org/10.1016/j.opresp.2023.100232>.
88. Grupo de Respiratorio en Atención Primaria – GRAP. Proyecto Asthma Right Care España. Available from: <https://www.sociedadgrap.com/proyecto-asthma-right-care-espana>.
89. Sociedad Española de Alergología e Inmunología Clínica (SEALC). Soy experto en alergia. Available from: <https://soyexpertoenalergia.es/>.
90. Ajuntament de Barcelona. Proyecto de acción comunitaria Radars. Servicios Sociales. Available from: <https://ajuntament.barcelona.cat/serveissocials/es/canal/proyecto-daccio-comunitaria-radars>.
91. Ayuntamiento de Madrid. Madrid te Acompaña. Available from: <https://www.madrid.es/portales/munimadrid/es/Inicio/Madrid-te-Acompaña/?vgnnextoid=40d1b1996f8bd710VgnVCM2000001f4a900aRCRD&vgnnextchannel=1ccd566813946010VgnVCM100000d0ca8c0RCRD>.
92. Consejo General de Colegios Oficiales de Farmacéuticos. Escuelas Rurales de Salud; 2023. Available from: <https://www.farmaceuticos.com/farmaceuticos/farmacia/farmacia-asistencial/escuelas-rurales-de-salud/>.
93. Consejo General de Colegios Oficiales de Farmacéuticos. Medicamento Accesible Plus. Available from: <https://www.farmaceuticos.com/farmaceuticos/recursos-farmaceuticos/apps-farmaceuticas/medicamento-accesible-plus/>.
94. Bergen N, Kirkby K, Nambiar D, et al. Monitoring of health inequalities to improve health equity. *Bull World Health Organ*. 2025;103, <http://dx.doi.org/10.2471/BLT.24.293053>, 231–231A.
95. World Health Organization. Health inequality monitoring. Harnessing data to advance health equity; 2024. Available from: <https://iris.who.int/bitstream/handle/10665/379703/9789240102606-eng.pdf>.